Rigel Pharma (RIGL) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $46.64 +1.72%
EPS Growth %: -34.9%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -34.9%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.97 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Barclays says AI trade is maturing, favors greater diversification
- Amneal gets FDA approval for lanreotide injection, launches immediately
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
